Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025

About this update from Medincell Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/0b3b102d212420dcf49d620c59d6f441"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dg.eaZEouqBL2QMBEcKR2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0b3b102d212420dcf49d620c59d6f441","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zZV0SFpJjLV3QeCFsLQ9wA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0b3b102d212420dcf49d620c59d6f441","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, December 01, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Medincell (Paris:MEDCL) will hold a videoconference on Tuesday December 9, 2025 to present the half-year financial results (April 2025-September 2025)","length":150,"tagName":"p"},{"type":"text","content":"> Meeting in French, 6:00 pm (CET): https://www.medincell.com/fr/live-fr/","length":76,"tagName":"p"},{"type":"text","content":"> Meeting in English, 7:00 pm (CET): https://www.medincell.com/live-en/","length":74,"tagName":"p"},{"type":"text","content":"Shareholders are invited to send their questions to [email protected], or through the chat system during the videoconference.","length":135,"tagName":"p"},{"type":"text","content":"About Medincell","length":15,"tagName":"p"},{"type":"text","content":"Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.","length":343,"tagName":"p"},{"type":"text","content":"These treatments combine active pharmaceutical ingredients with our proprietary BEPO® technology, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.","length":278,"tagName":"p"},{"type":"text","content":"Risperidone LAl was the first treatmen...

More updates from Medincell Sa